Enhanced Antitumor Efficacy and Reduced Systemic Toxicity of Sulfatide-Containing Nanoliposomal Doxorubicin in a Xenograft Model of Colorectal Cancer

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lin, Jia ^a   Yu, Yan ^a   Shigdar, Sarah ^a   Fang, Ding Zhi ^b   Du, Jun Rong ^b   Wei, Ming Q ^c   Danks, Andrew ^d   Liu, Ke ^b   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b SICHUAN UNIVERSITY   (China)

^c GRIFFITH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; SULFATIDE; SULFATIDE CONTAINING NANOLIPOSOME; TROPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CARDIOTOXICITY; CELL NUCLEUS; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; MALE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; SULFOGLYCOSPHINGOLIPIDS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84868712269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049277     Document Type: Article

References (46)

1. Sala-Vila A, Calder PC, (2011) Update on the relationship of fish intake with prostate, breast, and colorectal cancers. Crit Rev Food Sci Nutr 51: 855-871.
2. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, et al. (2002) Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 62: 781-788.
3. Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, et al. (2009) Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 8: 155-162.
4. Segal NH, Saltz LB, (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60: 207-219.
5. Wang AZ, Langer R, Farokhzad OC, (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63: 185-198.
6. Sawant RR, Torchilin VP, (2012) Challenges in development of targeted liposomal therapeutics. AAPS J 14: 303-315.
7. Davis ME, Chen Z, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
8. Park K, (2007) Nanotechnology: What it can do for drug delivery. J Control Release 120: 1-3.
9. Torchilin VP, (2006) Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting. Annu Rev Biomed Eng 8: 343-375.
10. Shao K, Hou Q, Duan W, Go ML, Wong KP, et al. (2006) Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 115: 150-157.
11. Shao K, Hou Q, Go ML, Duan W, Cheung NS, et al. (2007) Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci 64: 506-515.
12. Townson K, Greenshields KN, Veitch J, Nicholl D, Eckhardt M, et al. (2007) Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology 17: 1156-1166.
13. He H, Nilsson CL, Emmett MR, Ji Y, Marshall AG, et al. (2010) Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan. Glycoconj J 27: 27-38.
14. Brellier F, Chiquet-Ehrismann R, (2012) How do tenascins influence the birth and life of a malignant cell? Journal of Cellular and Molecular Medicine 16: 32-40.
15. De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, et al. (2006) Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res 12: 2191-2196.
16. Mukaratirwa S, Koninkx JF, Gruys E, Nederbragt H, (2005) Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture. Int J Exp Pathol 86: 219-229.
17. Stewart JCM, (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104: 10-14.
18. Alvarez-Cedron L, Sayalero ML, Lanao JM, (1999) High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl 721: 271-278.
19. Urva SR, Shin BS, Yang VC, Balthasar JP, (2009) Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 877: 837-841.
20. Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, et al. (2009) Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 26: 914-925.
21. Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, et al. (2009) Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 382: 254-261.
22. Elbayoumi TA, Torchilin VP, (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15: 1973-1980.
23. Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, et al. (2005) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107: 262-275.
24. Li X, Ding L, Xu Y, Wang Y, Ping Q, (2009) Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 373: 116-123.
25. Adams E, (1948) A method for counting blood platelets in small animals. Yale J Biol Med 21: 17-20.
26. Oliveira RAG, Takadachi MM, Nonoyama K, Barretto OCdO (2003) The absolute recommendation of chamber Neubauer method for platelets counting instead of indirect methods in severe thrombocytopenic patients. Rio de Janeiro 39.
27. Singal PK, Iliskovic N, (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905.
28. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, et al. (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17: 2237-2243.
29. Koh E, Nakamura T, Takahashi H, (2004) Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68: 163-167.
30. Wang J, Goh B, Lu W, Zhang Q, Chang A, et al. (2005) In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28: 822-828.
31. Li B, Xu H, Li Z, Yao M, Xie M, et al. (2012) Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int J Nanomedicine 7: 187-197.
32. Allen TM, Cheng WWK, Hare JI, Laginha KM, (2006) Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer. Anticancer Agents Med Chem 6: 513-523.
33. Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, et al. (1999) Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Cancer Res 5: 687-693.
34. Unezaki S, Maruyama K, Takahashi N, Koyama M, Yuda T, et al. (1994) Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res 11: 1180-1185.
35. Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, et al. (2012) Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine 7: 2007-2017.
36. Xu L, Anchordoquy T, (2011) Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 100: 38-52.
37. Wu J, Lu Y, Lee A, Pan X, Yang X, et al. (2007) Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10: 350-357.
38. Oudard S, Thierry A, Jorgensen TJ, Rahman A, (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28: 259-265.
39. Manil L, Couvreur P, Mahieu P, (1995) Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharm Res 12: 85-87.
40. Charrois GJ, Allen TM, (2003) Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609: 102-108.
41. Campbell RB, (2006) Tumor Physiology and Delivery of Nanopharmaceuticals. Anticancer Agents Med Chem 6: 503-512.
42. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D, (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
43. Alexis F, Pridgen E, Molnar LK, Farokhzad OC, (2008) Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Mol Pharm 5: 505-515.
44. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, et al. (2011) Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17: 867-874.
45. Miura R, Aspberg A, Ethell IM, Hagihara K, Schnaar RL, et al. (1999) The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion. J Biol Chem 274: 11431-11438.
46. Pesheva P, Gloor S, Schachner M, Probstmeier R, (1997) Tenascin-R is an intrinsic autocrine factor for oligodendrocyte differentiation and promotes cell adhesion by a sulfatide-mediated mechanism. J Neurosci 17: 4642-4651.